---
title: "Xolair (omalizumab) in allergic asthma: Specific populations questions"
description: "Specific populations questions on Xolair (omalizumab) in allergic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Is Xolair safe during pregnancy? Can you breastfeed while taking Xolair? Is Xolair approved for children with asthma? Is Xolair safe for older adults with asthma? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/xolair--allergic-asthma/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab) in allergic asthma: Specific populations questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)

Questions that apply to every indication of Xolair are on [Xolair (omalizumab), all indications](https://www.evicenter.com/medical-information/xolair).

## Pregnancy and breastfeeding

<a id="xolair-pregnancy"></a>

### Is Xolair safe during pregnancy?

> “A registry study of XOLAIR exposure during pregnancy showed no increase in the rate of 
> major birth defects or miscarriage.”

Source: [XOLAIR: Prescribing information, page 23, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=23)

> “The EXPECT registry prospectively reported perinatal pregnancy outcomes from a cohort of 250 women with asthma who were exposed to omalizumab (XOLAIR) during pregnancy<sup>4,33</sup>”

Source: [XOLAIR: Pregnancy Registry | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/pregnancy-registry-data.html#:~:text=The%20EXPECT%20registry%20prospectively%20reported,exposed%20to%20omalizumab%20%28XOLAIR%29%20during)

> “Among applicable registry infants, the prevalence of major congenital anomalies (8.1%) 
> was similar to that for infants in the comparator cohort (8.9%).  Among applicable registry 
> pregnancies, 99.1% led to live births, similar to 99.3% for the comparator cohort. There 
> was an increased rate of low birth weight among registry infants (13.7%) as compared to 
> the comparator cohort (9.8%); however, women taking XOLAIR during pregnancy also had 
> more severe asthma, which makes it difficult to determine whether the low birth weight is 
> due to the drug or the disease severity.”

Source: [XOLAIR: Prescribing information, page 24, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=24)

> “The registry study cannot definitively establish the absence of any risk because of 
> methodological limitations, including the observational nature of the registry, small sample 
> size, and potential differences between the registry population and the comparator cohort.”

Source: [XOLAIR: Prescribing information, page 24, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=24)

> “Pregnancy: Data with XOLAIR use in pregnant women are insufficient to inform on drug associated risk.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Pregnancy%3A%20Data%20with%20XOLAIR%20use,inform%20on%20drug%20associated%20risk.)

Note: The Important Safety Information page summarizes the pregnancy data as insufficient to inform on drug-associated risk; section 8.1 of the Prescribing Information summarizes the registry results quoted here.

<a id="xolair-breastfeeding"></a>

### Can you breastfeed while taking Xolair?

> “There is no information regarding the presence of omalizumab in human milk, or the effects 
> on milk production.  However, omalizumab is a human monoclonal antibody (IgG1 kappa), 
> and immunoglobulin (IgG) is present in human milk in small amounts.   
> The majority of infants (80.9%, 186/230) in the pregnancy exposure registry were breastfed.  
> Events categorized as “infections and infestations” were not significantly increased in infants 
> who were exposed to XOLAIR through breastfeeding compared with infants who were not 
> breastfed, or infants who were breastfed without exposure to XOLAIR. 
>
> The developmental and health benefits of breastfeeding should be considered along with the 
> mother’s clinical need for XOLAIR and any potential adverse effects on the breastfed child 
> from omalizumab or from the underlying maternal condition.”

Source: [XOLAIR: Prescribing information, page 25, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=25)

## Pediatric use

<a id="xolair-pediatric-use"></a>

### Is Xolair approved for children with asthma?

> “Safety and effectiveness of XOLAIR for moderate to severe persistent asthma who had a 
> positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are 
> inadequately controlled with inhaled corticosteroids, have been established in pediatric 
> patients aged 6 years and older.”

Source: [XOLAIR: Prescribing information, page 25, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=25)

> “Safety and efficacy in pediatric patients with asthma below 6 years of age have not been 
> established.”

Source: [XOLAIR: Prescribing information, page 25, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=25)

## Specific populations

<a id="xolair-older-adults"></a>

### Is Xolair safe for older adults with asthma?

> “In clinical studies, 134 asthma patients, 20 CRSwNP patients, 37 CSU patients and no IgE-
> mediated food allergy patients 65 years of age or older were treated with XOLAIR.  
> Although there were no apparent age-related differences observed in these studies, the 
> number of patients aged 65 and over is not sufficient to determine whether they respond 
> differently from younger patients.”

Source: [XOLAIR: Prescribing information, page 26, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=26)

> “The population pharmacokinetics of omalizumab was analyzed to evaluate the effects of 
> demographic characteristics in patients with asthma.  Analyses of these data suggested that 
> no dose adjustments are necessary for age (6 to 76 years), race, ethnicity, or gender.”

Source: [XOLAIR: Prescribing information, page 29, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=29)

Note: The first passage covers every indication; 134 of the patients 65 years of age or older had asthma.

## Related pages
- [Medical information: Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)
- [Indication](https://www.evicenter.com/medical-information/xolair--allergic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xolair--allergic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/xolair--allergic-asthma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xolair--allergic-asthma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/xolair--allergic-asthma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair--allergic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair--allergic-asthma/access-and-coverage)
